South Africa

China’s Junshi Potential COVID-19 Drug Promises in Small Experiment – SABC News

According to a small clinical study, an antiviral oral drug developed jointly by a subsidiary of Shanghai Junshi Biosciences and other Chinese institutes proved to be promising to accelerate the virus in COVID-19 patients early on.

The medicine VV116 is a derivative of Gilead SciencesInc COVID-19 remdesivir and was approved for use in Uzbekistan last year in moderate to severe cases.

The viral load period defined by the experimental researchers as the time between the first positive COVID-19 test result and the first negative result was 8.56 days for participants who received the experimental treatment within five days of the first positive test result.

This was shorter than 11.13 days in the control group, according to expert assessments.
The study included 136 mild to moderate adult COVID-19 infections in March in China.

The researchers reported in an article in Emerging Microbes & Infections that participants received five days of oral medication along with standard treatment or just standard treatment.

Overall, there was no significant difference in the period of virus spread between those who took VV116 more than five days after the first positive result and the control group.

The limitations of the study included the small experimental size and a higher proportion of participants in the control group who reported symptoms, which could lead to potential bias, which the researchers had to correct for the statistical model.

The drug III. Phase I study to evaluate its effectiveness in mild to moderate patients compared to Pfizer Inc Paxlovid oral tablets and a separate phase III study. phase study in moderate and severe cases.

China has approved an antibody-based injection of Paxlovid and Brii Biosciences Ltd. in patients with mild to moderate COVID-19 who are at high risk of developing a serious condition.

China’s Junshi Potential COVID-19 Drug Promises in Small Experiment – SABC News

Source link China’s Junshi Potential COVID-19 Drug Promises in Small Experiment – SABC News

Back to top button